Publications by authors named "Yelena Broytman"
Article Synopsis
- The objective was to create a web-based AI tool that predicts drug sustainability (DS) for infliximab and vedolizumab in patients with moderate-to-severe Ulcerative Colitis (UC), addressing a gap in reliable prediction methods.!
- The study included data from three Israeli medical centers, analyzing patients treated for over 54 weeks without corticosteroids, hospitalizations, or surgeries, using machine learning for accurate predictions based on baseline clinical data.!
- The developed model showed strong predictive performance with an area under the ROC curve of 0.86 and accuracy ranging from 65.5% to 76.9%, promising improvements in clinical decision-making for managing UC while enhancing precision medicine practices.!
Background And Aim: Drug sustainability (DS) is a surrogate marker for treatment efficacy. We aimed to compare the DS of two main biologics used to treat moderate-to-severe ulcerative colitis (UC), infliximab (IFX) and vedolizumab (VDZ), in a real-world setting.
Methods: We conducted a retrospective cohort study at a tertiary medical center in Israel.
Article Synopsis
- A study examined the effectiveness of biologic early prophylaxis for preventing endoscopic post-operative recurrence (ePOR) in Crohn's disease patients after ileocecal resection (ICR).
- It included 297 patients and found that ePOR occurred in about 41.8% of cases within one year, with varying rates across treatment groups: 40.2% for anti-TNF, 33% for vedolizumab (VDZ), and 61.8% for ustekinumab (UST).
- The results indicated no significant differences in ePOR risk between the anti-TNF therapy and the other biologics after adjusting for patient factors, suggesting early prevention was effective for around 60% of patients regardless of